aid: blossomhill-therapeutics
name: BlossomHill Therapeutics
description: 'BlossomHill Therapeutics is a privately held, clinical-stage biopharmaceutical
  company headquartered in San Diego, California, founded in 2020 by drug designer J.
  Jean Cui, Ph.D. and biotech operator Y. Peter Li, Ph.D., M.B.A. It develops intelligently
  designed small-molecule medicines for oncology and autoimmune disease, led by BH-30643,
  a first-in-class macrocyclic non-covalent mutant-selective OMNI-EGFR inhibitor for
  EGFR- and HER2-mutated non-small cell lung cancer, and BH-30236, a macrocyclic CLK
  inhibitor for relapsed or refractory acute myeloid leukemia and higher-risk myelodysplastic
  syndrome. The company is a drug discovery business, not a software vendor: it publishes
  no public API, SDK, developer portal or machine-readable specification.'
image: https://bhtherapeutics.com/wp-content/uploads/logo-stacked.svg
url: https://raw.githubusercontent.com/api-evangelist/blossomhill-therapeutics/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
specificationVersion: '0.23'
created: '2026-08-07'
modified: '2026-08-07'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Oncology
- Drug Discovery
- Clinical Trials
- Life Sciences
- Precision Medicine
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/blossomhill-therapeutics-domain-security.yml
- type: Website
  url: https://bhtherapeutics.com/
- type: About
  url: https://bhtherapeutics.com/about-us/
- type: Pipeline
  url: https://bhtherapeutics.com/pipeline/
- type: Investors
  url: https://bhtherapeutics.com/investors/
- type: Blog
  url: https://bhtherapeutics.com/news/
- type: PressReleases
  url: https://bhtherapeutics.com/press-releases/
- type: BlogRSS
  url: https://bhtherapeutics.com/feed/
- type: Contact
  url: https://bhtherapeutics.com/contact/
- type: Careers
  url: https://bhtherapeutics.com/careers/
- type: TermsOfService
  url: https://bhtherapeutics.com/terms-of-service/
- type: PrivacyPolicy
  url: https://bhtherapeutics.com/privacy-policy/
- type: CookiePolicy
  url: https://bhtherapeutics.com/cookie-policy/
- type: LLMsTxt
  url: llms/blossomhill-therapeutics-llms.txt
  name: llms.txt (published, but every link points at staging)
  description: 'Harvested verbatim from https://bhtherapeutics.com/llms.txt (HTTP 200,
    generated by All in One SEO 4.9.10). Recorded as-published and unusable as an agent
    surface: every one of the 33 URLs it advertises — the sitemap, all 13 pages and all
    17 team profiles — points at the Kinsta build/staging host stg-blossomhill-build.kinsta.cloud,
    which answers HTTP 401 to anonymous requests, rather than at the production host
    bhtherapeutics.com. Probed 2026-08-07.'
- type: LinkedIn
  url: https://www.linkedin.com/company/blossomhill-therapeutics-inc
- type: Twitter
  url: https://twitter.com/bhtherapeutics
- type: SecondaryMarket
  url: https://forgeglobal.com/blossomhill-therapeutics_stock/
x-enrichment:
  date: '2026-08-07'
  status: minimal
  artifacts_added: 2
  pass: local-v1
x-coverage:
  state: none
  reason: not-a-software-company
  detail: >-
    BlossomHill is a clinical-stage oncology drug-discovery company with no developer
    site and no API product; every OpenAPI, GraphQL, MCP and agent-card path on
    bhtherapeutics.com returns 404, api./docs./developer.bhtherapeutics.com do not
    resolve, and the only machine-readable surface on the domain is the default
    WordPress /wp-json REST root its marketing CMS exposes.
  evidence:
    - url: https://bhtherapeutics.com/openapi.json
      status: 404
    - url: https://bhtherapeutics.com/.well-known/agent-card.json
      status: 404
    - url: https://bhtherapeutics.com/graphql
      status: 404
    - url: https://bhtherapeutics.com/wp-json/
      status: 200
    - url: https://stg-blossomhill-build.kinsta.cloud/
      status: 401
  checked: '2026-08-07'